| Ticker: IMPH | 1010 Third Avenue, Suite 302 | |
| Exchange: NASDAQ-National Market | New York, New York 10021 | |
| Industry: High-Tech | (212) 702-8300 |
| Type of Shares: | Common Shares | Filing Date: | 11/2/95 | |
| U.S. Shares: | 1,950,000 | Offer Date: | 2/20/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 1,950,000 | Offer Price: | $13.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.91 | |
| Offering Amount: | $23,400,000 | Selling: | $0.55 | |
| Expenses: | $1,050,000 | Reallowance: | $0.10 | |
| Shares Out After: | 4,936,274 |
| Manager | Tier | Phone |
| Salomon Brothers Inc. | Lead Manager | (212) 783-2947 |
| Prudential Securities Incorporated | Co-manager | (212) 214-3000 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $10.01 | $10.53 | $7.03 | Assets: | $7.49 |
| Net Income: | $0.87 | $0.86 | $0.39 | Liabilities: | $1.94 |
| EPS: | $0.33 | $0.26 | Equity: | $5.55 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a leader in providing critical information focused exclusively on cancer. The company provides the expertise to establish correct diagnosis, accurate prognosis, treatment determination and patient follow-up, all of which are essential for making medically optimal and cost-effective cancer management decisions. IMPATH believes it currently performs more specialized analyses to establish correct diagnosis of difficult cancer cases than any other institution in the world. The company also believes it is the leader in providing the most comprehensive prognostic information essential to the management of breast cancer. IMPATH provided patient specific prognostic information on over 10% of all such cases in the U.S. last year and over 20% of cases diagnosed in the New York Metropolitan areas, the company's largest market. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund the continued development and expansion of its diagnostic and prognostic database (including selected acquisitions, as appropriate), increase its working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.